Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

CAN2007 was a phase 1/2 study of once- and twice-weekly single-agent bortezomib in relapsed primary systemic amyloid light chain amyloidosis (AL) amyloidosis. Seventy patients were treated, including 18 and 34 patients at the maximum planned doses on the once- and twice-weekly schedules. This prespe...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Reece, Donna E., Hegenbart, Ute, Sanchorawala, Vaishali, Merlini, Giampaolo, Palladini, Giovanni, Bladé, Joan, Fermand, Jean-Paul, Hassoun, Hani, Heffner, Leonard, Kukreti, Vishal, Vescio, Robert A., Pei, Lixia, Enny, Christopher, Esseltine, Dixie-Lee, van de Velde, Helgi, Cakana, Andrew, Comenzo, Raymond L.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2014
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4199951/
https://ncbi.nlm.nih.gov/pubmed/25202139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-04-568329
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items